

1 Different subtypes of influenza A viruses target different human proteins and pathways  
2 leading to different pathogenic phenotypes

3 Yujie Wang<sup>1,2\*</sup>, Ting Song<sup>1\*</sup>, Kaiwu Li<sup>1</sup>, Yuan Jin<sup>1</sup>, Junjie Yue<sup>1§</sup>, Hongguang Ren<sup>1§</sup>, Long Liang<sup>1§</sup>.

4 <sup>1</sup>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Biotechnology, Beijing 100071,  
5 China

6 <sup>2</sup>Institute of Physical Science and Information Technology, Anhui University, Hefei, Anhui 230601,  
7 China

8 \*These authors contributed equally to this work.

9 §Correspondence: bioren@163.com (H.R.); ll@bmi.ac.cn (L.L.); yue\_junjie@126.com (J.Y.)

## 10 **Abstract**

11 Different subtypes of Influenza A viruses cause different pathogenic phenotypes  
12 after infecting human bodies. Direct binary interactions between viral proteins and  
13 human proteins provide an important background for influenza viruses to cause complex  
14 pathologies of hosts. Here, we demonstrated the different impacts on the TNF- $\alpha$ -induced  
15 NF- $\kappa$ B activation of H1N1 and H5N1 virus proteins. By further examining the virus-host  
16 protein-protein interactions (PPI), we found that the same segment protein of the H1N1  
17 and H5N1 viruses target on different host proteins. We then performed a yeast  
18 two-hybrid analysis of a highly pathogenic avian H5N1 influenza virus and human  
19 proteins. Influenza-host protein-protein interaction networks of three strains of

20 influenza A viruses (including two other reported influenza-host PPI networks) were  
21 systematically compared and mapped on the network level and the pathway level. The  
22 results show subtype-specific characters of the influenza-host protein interactome,  
23 which may response for the specific pathogenic mechanisms of different subtypes of  
24 influenza viruses.

## 25 **Importance**

26 Influenza A virus (IAV) can cause contagious respiratory illness, namely influenza (flu).  
27 The symptoms of infections from different subtypes of IAVs vary from mild to severe  
28 illness. The mechanism of these different pathogenic phenotypes remains poorly  
29 understood. Our results show that the same NA and NP segments from H1N1 and H5N1  
30 virus cause different impacts on the TNF- $\alpha$ -induced NF- $\kappa$ B pathway. Furthermore, we  
31 generated a yeast two-hybrid protein-protein interaction (PPI) network between H5N1  
32 and human proteins. By systematically comparing the influenza-host PPI networks of  
33 three strains of IAVs, we show that different subtypes of IAVs target different human  
34 proteins and pathways, which may have led to different pathogenic phenotypes.

## 35 **Introduction**

36 Influenza A virus (IAV) belongs to the Orthomyxoviridae family. Its genome consists  
37 of eight segmented, negative-strand RNA [1-3]. IAV are further typed into many different

38 subtypes based on the antigenicity of hemagglutinin (HA) and the neuraminidase (NA)  
39 [4]. Currently, 18 HA(H1-H18) and 11 NA (N1-N11) subtypes have been identified in IAVs  
40 [5]. Aquatic birds are considered to be the natural reservoirs of IAVs and the source of all  
41 IAVs in other animals such as human, poultry, wild birds, swine, equine and so on [6-8].  
42 Widespread hosts, the lack of proofreading activity of the viral polymerase during  
43 genome replication and the segmented nature of genome enable IAVs rapidly evolve  
44 though the accumulation of mutations and genome reassortment [9, 10], leaving an  
45 increasing evolution diversity of the IAV and constantly emerged novel IAVs [11], which  
46 poses a serious threat to human lives and economic development.

47 Different viruses may have evolved various mechanisms to co-opt host processes  
48 and suppress host defenses, inducing different infectious phenotypic outcomes. H1N1 is  
49 one of the main seasonal IAVs, which are annually recurrent and are mutually infectious  
50 among human population[12, 13]. Highly pathogenic (HP) avian influenza virus (AIV)  
51 H5N1 have jumped host barriers and caused human infections since 1997 [14].  
52 According to the monitoring report from WHO, H5N1 AIVs have resulted in 860 human  
53 infections and 453 deaths as of November 1, 2018 [15]. Constantly reported sporadic  
54 human infectious with H5N1 and its high mortality warn us that H5N1 AIV may cause  
55 serious epidemic worldwide. It is necessary to improve the epidemiological surveillance  
56 and the research of pathogenic mechanism on these important subtypes of influenza  
57 viruses.

58 Both H1N1 and H5N1 influenza viruses have posed tremendous health threats in

59 many regions worldwide, but their transmissibility, virulence and fatality are quite  
60 different [16]. Although characterized by high transmissibility, the virulence and fatality  
61 of the H1N1 influenza virus are relatively low. The reverse holds true for H5N1 influenza.  
62 With a fatality rate that exceeds 60%, it is known to cause severe damage to the human  
63 respiratory system, but the virus is not presently capable of efficient transmission from  
64 human to human.

65 An important step to understand the pathogenesis of the pathogens is to  
66 investigate the protein-protein interactions between the host and pathogens. Influenza  
67 A viruses infect hosts through complex mechanisms, among which direct binary  
68 interactions between influenza A viral proteins and host proteins play an important role  
69 during the process influenza viruses invade hosts. The innate immune system is the first  
70 barrier to prevent pathogen invasion. The NF- $\kappa$ B signaling pathway is an important part  
71 of the innate immune system, which plays a key role in the induction of the innate  
72 immune response against viral infection. The important role of NF- $\kappa$ B signaling pathway  
73 in resisting virus invasion makes it a hot topic in current research [17-20]. In mammals,  
74 there are two major NF- $\kappa$ B signaling pathways: the canonical NF- $\kappa$ B pathway and the  
75 noncanonical NF- $\kappa$ B pathway [21, 22]. Under the stimulation of pathogenic microbial  
76 infections or their induced inflammatory factors, NF- $\kappa$ B is normally activated by classical  
77 signaling pathways [23]. Briefly, NF- $\kappa$ B dimers are retained in the cytoplasm by binding to  
78 inhibitory I $\kappa$ B proteins, binding of certain ligands and cell surface receptors recruits  
79 downstream adaptor proteins, then they recruit IKK complexes and lead to the activation

80 of IKK complexes [23, 24]. IKK complexes, especially the IKK $\beta$  subunit, phosphorylate two  
81 serine residues of the I $\kappa$ B protein, resulting in ubiquitination and proteasome-dependent  
82 degradation of the I $\kappa$ B protein, which releasing NF- $\kappa$ B into the nucleus to activate  
83 downstream gene transcription [25, 26]. The non-canonical NF- $\kappa$ B signaling pathway  
84 mainly activates the signal molecule NIK kinase, which in turn phosphorylates a complex  
85 containing two IKK $\alpha$  subunits [27]. The IKK $\alpha$  complex phosphorylates and cleaves p100,  
86 thereby promoting the form of p52/RelB dimerization which then activates transcription  
87 of specific genes [28, 29].

88 Diverse bacterial and viral pathogens target NF- $\kappa$ B signaling pathway to evade host  
89 immune defenses. Some viruses suppress NF- $\kappa$ B activation to dampen the host immune  
90 responses to maintain latency [30]. For example, human bocavirus (HBoV) proteins NS1  
91 and NS1-70 [31], the mumps virus (MuV) small hydrophobic protein (SH) [32] and  
92 Molluscum contagiosum virus (MCV) protein MC005 [33] inhibit TNF- $\alpha$ -mediated  
93 activation of NF- $\kappa$ B by reducing the phosphorylation of IKK $\beta$ , I $\kappa$ B $\alpha$ , and p65 as well as the  
94 translocation of p65 into the nucleus. Some viral pathogens activate NF- $\kappa$ B for viral gene  
95 expression, replication and spread. For example, the K15 protein of KSHV and the early  
96 protein Nef of most primate lentiviruses enhances NF- $\kappa$ B activation to initiate proviral  
97 transcription [34, 35]. Influenza A viruses can also interfere with antiviral responses by  
98 regulating the NF- $\kappa$ B signaling pathway. Studies have shown that influenza virus proteins  
99 interact with NF- $\kappa$ B to promote viral replication. For example, the IAV NS1 protein  
100 specifically inhibits IKK-mediated NF- $\kappa$ B activation and production of the NF- $\kappa$ B induced

101 antiviral genes by physically interacting with IKK through the C-terminal effector domain  
102 [36].

103 In this paper, we used the luciferase assay and the Co-immunoprecipitation  
104 experiment to study how the NP and NA viral proteins of both H1N1 and H5N1 interact  
105 with NF- $\kappa$ B signaling pathway. We found that the H1N1 NP has little impact on the  
106 TNF- $\alpha$ -induced NF- $\kappa$ B transcriptional activation while the H5N1 NP inhibits the  
107 TNF- $\alpha$ -induced NF- $\kappa$ B transcriptional activation by coimmunoprecipitating with IKK $\alpha$ .  
108 Furthermore, the H5N1 NP suppresses the phosphorylation of I $\kappa$ B $\alpha$ , IKK $\alpha$  as well as the  
109 translocation of p65 into the nucleus of infected A293 cells. We also found that the  
110 H5N1 NA activates the IL-1 $\beta$ -induced NF- $\kappa$ B transcriptional activation by  
111 coimmunoprecipitating with TAB2, while H1N1 NA inhibits the IL-1 $\beta$ -induced NF- $\kappa$ B  
112 transcriptional activation by coimmunoprecipitating with IKK $\beta$ .

113 Then, we used a yeast two-hybrid approach to generate an influenza-host  
114 protein-protein interaction network for a highly pathogenic avian H5N1 influenza virus  
115 A/Goose/Jilin/hb/2003. In order to investigate the pathogenic conservations and  
116 distinctions for different influenza virus subtypes, we introduced two other previously  
117 reported influenza-host PPI networks (the H1N1 strain A/PR/8/34 and the H3N2 strain  
118 A/Udorn/72) [37]. We systematically mapped and compared the pathogen-host protein  
119 interactions between proteins from three strains of different influenza A virus subtypes  
120 and human proteins. By identifying shared and distinct host-pathogen protein  
121 interaction patterns for these influenza A viruses, we enlightened how they exploit

122 distinctive strategies to subvert cellular pathways toward disease progression.

## 123 **Results**

### 124 **1 H5N1 NP and H1N1 NP have different impacts on TNF- $\alpha$ -induced NF- $\kappa$ B activation.**

125 Nucleoprotein (NP) is an important component of ribonucleoprotein (RNP) complex  
126 playing crucial role in influenza virus life cycle together with other polymerase proteins  
127 (PB1 and PA). At the onset of replication, NP functions as an adapter between the virus  
128 and host cell processes to maintain the viral genome integrity. After release of RNP into  
129 the cell cytoplasm, NP interacts with many macromolecules of cellular origin to facilitate  
130 transcription, replication and translation of viral genome [6, 38].

131 TNF- $\alpha$  plays an important role in host defense against viral infection. During the IAV  
132 infection, the elevated level of TNF- $\alpha$  is detected in serum. To determine the impact of  
133 NP on the activation of the NF- $\kappa$ B pathway, we evaluated the impact of the H5N1 and  
134 H1N1 NP coding sequence on NF- $\kappa$ B activation by using an NF- $\kappa$ B promoter reporter  
135 system (Fig. 1A, Fig. 1B). Those results show that H5N1 NP inhibits TNF- $\alpha$ -induced NF- $\kappa$ B  
136 transcriptional activation while the H1N1 NP has little impact on it, which confirming  
137 that H5N1 NP has an inhibitory effect on NF- $\kappa$ B signaling pathway, but the specific site  
138 and mechanism remain unclear. Then we searched for potential targets through the  
139 luciferase assay. Those results (Fig. S1) show that the potential targets of H5N1 NP on  
140 the NF- $\kappa$ B signaling pathway are IKK $\alpha$  and the complex of TAK. To decide the exact target

141 of H5N1 NP, we investigated whether the H5N1 NP protein physically interacts with IKK $\alpha$   
142 and the complex of TAK by the essay of Co-Immunoprecipitation. The results (Fig. 1C, Fig.  
143 1D) show that there are protein-protein interactions between H5N1 NP and TAK1 and  
144 IKK $\alpha$  in cells, indicating that the H5N1 NP inhibits the NF- $\kappa$ B signaling pathway by  
145 targeting TAK1 and IKK $\alpha$ .

146 We then examined whether H5N1 NP can modulate its activation. The activation of  
147 IKK $\alpha$  by phosphorylation is required to the phosphorylation of I $\kappa$ B. We tested whether  
148 H5N1 NP played a role in inhibiting the phosphorylation of the IKK $\alpha$ . The results show  
149 that the level of phosphor-IKK $\alpha$  in empty vector-transfected cells was more than that in  
150 H5N1 NP-expressing cells (Fig. 1E), indicating that the H5N1 NP protein suppresses  
151 TNF- $\alpha$ -mediated IKK $\alpha$  phosphorylation.

## 152 **2 H5N1 NA and H1N1 NA have different impacts on IL-1 $\beta$ -induced NF- $\kappa$ B activation.**

153 Neuraminidase (NA) is an integral membrane glycoprotein and a second major  
154 surface antigen of the virion. NA cleaves terminal sialic acid from glycoproteins or  
155 glycolipids. Thus, it functions to free virus particles from host cell receptors, to permit  
156 progeny virions to escape from the cell in which they arose, and so facilitate virus spread  
157 [6, 10].

158 We studied the differences in the impacts of the NA proteins of H5N1 and H1N1 NA  
159 on the NF- $\kappa$ B signaling pathways using a similar method through an NF- $\kappa$ B promoter  
160 reporter system. Reporter plasmid p NF- $\kappa$ B-luc and internal control plasmid pRL-TK,  
161 together with pH5N1 NA and pH1N1 NA or empty vector, were cotransfected into 293T



162 cells. At 24h post-transfection, cells were mock-treated or treated with human IL-1 $\beta$  for  
163 6h. The H5N1 NA clone significantly promoted IL-1 $\beta$ -stimulated NF- $\kappa$ B promoter activity  
164 (Fig. 2A) while H1N1 NA has inhibitory impact on it (Fig. 2B). This result indicates that  
165 H5N1 NA promotes IL-1 $\beta$ -induced NF- $\kappa$ B transcriptional activation while H1N1 NP  
166 inhibits it.

167 The potential target of H5N1 NA on the NF- $\kappa$ B signaling pathway is the complex of  
168 TAK (Fig. S2) while the potential targets of H1N1 NA on the NF- $\kappa$ B signaling pathway are  
169 TAB2 and IKK $\beta$  (Fig. S3). Then we also studied the difference of interaction sites between  
170 H5N1 NA and H1N1 NA with the NF- $\kappa$ B signaling pathway by the essay of  
171 Co-Immunoprecipitation. The result is that H5N1 NA interacts with NF- $\kappa$ B signaling  
172 pathway at TAB2 (Fig. 2C) while H1N1 NA interact with NF- $\kappa$ B signaling pathway at IKK $\beta$   
173 (Fig. 2D), which demonstrate that H5N1 NA and H1N1 NA have different sites that  
174 interact with the NF- $\kappa$ B signaling pathway.

### 175 **3 Identification of Human Factors that Interacts with Influenza Viruses**

176 Then we seek to find out the virus-host relations of different subtypes of IAVs on a  
177 larger scale by comparing the influenza-host PPI networks. We used a yeast two-hybrid  
178 (Y2H) approach to identify direct binary interactions between proteins of an H5N1 strain  
179 and human proteins. One hundred and seventy-seven pairwise interactions between the  
180 8 viral proteins and the 140 human proteins were detected. (Fig. 3, Table S1).

181 Two previous reported influenza-host PPI network [37] were introduced in this  
182 paper for comprehensively comparison of networks. The first network contains 135

183 pairwise interactions between the H1N1 strain A/Human/PR/8/34 (“PR8”) and 87 human  
184 proteins, and the second network covers 81 pairwise of interactions between the H3N2  
185 strain A/Human/Udorn/72 (“Udorn”) and 66 human proteins. Both of these two  
186 pathogen-host networks were collected by using the Y2H approach. Our comparison and  
187 network mapping are based on these three influenza-host PPI networks.

188 We generated a human protein-protein interaction network based on the BioGRID  
189 interaction database [39], which contains 127950 interactions among 14924 human  
190 proteins (only the physical binary interactions are selected). We define the proteins in  
191 the human interaction network that directly interact with the influenza viruses as N1  
192 proteins, and first neighbors of the N1 proteins are defined as N2 proteins. To quantify  
193 the importance or the essentiality of proteins in the human PPI network, we use the  
194 degree centrality and a new centrality measurement (named as NC) based on edge  
195 clustering coefficient [40].

196 The network topological analysis shows that the viral proteins have a greater  
197 average degree in the influenza-host interaction network compared to that of human  
198 proteins in the human interaction network (Table 1). The N1 proteins and N2 proteins of  
199 influenza viruses on average interact with more proteins in the human interaction  
200 network than the others.

201 Based on the other centrality measure NC, both the N1 and N2 proteins of all the  
202 three stains of influenza viruses score higher than the average score of the proteins in  
203 the human interaction network, especially the N1 proteins of the H5N1 virus. In [41], the

204 authors proposed that pathogens may have evolved to interact with human proteins  
205 that are hubs (those involved in many interactions) or bottlenecks (those central to  
206 many pathways) [42] to disrupt key proteins in complexes and pathways. Our results also  
207 support this hypothesis. The connection patterns above hold for all the three  
208 influenza-host interaction networks, which implying that an influenza virus as a very  
209 compacted pathogen has to maximum its function by interacting with many important  
210 proteins in the hosts.

#### 211 **4 Different subtypes of influenza viruses show different virus-host interacting** 212 **patterns**

213 Although all the three strains of influenza viruses share many topological characteristics  
214 in the influenza-host interaction network, the direct interactors (N1 proteins) of different  
215 subtypes of influenza viruses do not actually overlap much (Fig. 4A). Only 6 proteins  
216 (Table 2) are shared by all the three strains as direct interactors. Table 2 has listed all the  
217 6 proteins and their viral interactors of different subtypes of influenza viruses. Although  
218 all the three strains of influenza viruses target directly at these six human proteins, the  
219 viral proteins they used are different. For example, the viral interactor of the TRAF1  
220 protein in the H5N1 strain is PB1, while the PR8 strain uses two different viral proteins  
221 (NP, PB2) to interact with TRAF1.

222 Despite the three influenza viruses share few direct interactors, they have much  
223 more in common at the N2 protein level (Figure 4B). In total, there are 829 proteins  
224 shared by all the three influenza viruses.

225 We then mapped the host interactors to pathways that may involve in the infection  
226 of influenza viruses. After filtering, four classes of pathways in the KEGG database [43]  
227 were considered: the immune system pathways, the cell growth and death pathways,  
228 the signal transduction pathways and pathways about inflammation. In total, sixty-five  
229 pathways were selected (Table S2).

230 Fifty-five out of sixty-five pathways have shown to be in contact with one or more  
231 strains of influenza viruses (Fig. 5), which prove the efficiency of our selection in  
232 canonical pathways to consider. These include some previously reported pathways that  
233 are related to influenza infection such as NF- $\kappa$ B, apoptosis, Wnt/ $\beta$ -catenin and MAPK  
234 pathways. There are twenty-two out of sixty-five pathways shown to be involved in the  
235 infection of all the three strains of influenza viruses.

236 Different subtypes of influenza viruses, though have few direct host interactors in  
237 common, show much in common at the indirect interactor level (N2 proteins) and the  
238 targeted pathway level. This fact implies that influenza viruses infect hosts by targeting  
239 functional modules or protein complex in the host PPI network rather than focusing on  
240 specific proteins to bind. More details of the relationships between influenza viruses and  
241 host pathways show that different influenza viruses use different viral proteins to target  
242 different host proteins in the pathways (Table S2).

## 243 **Discussion**

244 During the course of an influenza virus infection, viral proteins interact with an array

245 of host proteins and pathways, which defines the viral-host relationships. Different  
246 viral-host relationships lead to different pathogenesis of the virus. Human may be  
247 infected by several subtypes of influenza viruses, including H1N1, H3N2, H5N1, H7N9,  
248 H9N2. However, the symptoms of these infections vary from mild to severe illness. In  
249 this paper, we tried to uncover the subtype-specific viral-host relationships by examining  
250 the effects of viral proteins on the NF- $\kappa$ B signaling pathways. Furthermore, we  
251 comprehensively compared the influenza-host PPI networks of three strains of virus in  
252 different subtypes, including one that we constructed using the Y2H approach. The  
253 results imply that different subtypes of influenza A virus use different viral proteins to  
254 target on different human proteins and human cellular pathways, leading to different  
255 pathogenic phenotypes.

256 NF- $\kappa$ B is critical for innate immune defense to cope with invading microbial  
257 pathogens. Once there are viruses invading organisms, the host will manipulate the  
258 NF- $\kappa$ B signaling pathway to clean up them. To survive, the microbial pathogens have  
259 evolved various strategies to make use of the NF- $\kappa$ B signaling pathway to escape the  
260 innate immune of the host. Influenza viruses can also manipulate the NF- $\kappa$ B signaling  
261 pathway to promote their survival and replication. Interaction between influenza virus  
262 and NF- $\kappa$ B signaling pathway is essential for its pathogenesis.

263 H1N1 and H5N1 influenza viruses both have the nucleoprotein and neuraminidase,  
264 but their transmissibility, virulence and fatality are quite different [16]. Through our  
265 studies, we found H5N1 NP inhibits TNF- $\alpha$ -induced NF- $\kappa$ B transcriptional activation while

266 the H1N1 NP has little impact on it and H5N1 NA promotes IL-1 $\beta$ -induced NF- $\kappa$ B  
267 transcriptional activation while H1N1 NP inhibits it. The results show subtype-specific  
268 characters of the influenza-host protein interactome, which may response for the  
269 specific pathogenic mechanisms of different subtypes of influenza viruses.

270 We systematically compared and mapped the influenza-host PPI network of three  
271 stains of influenza viruses. Human interactors of different subtypes of influenza viruses  
272 have shown to be of similar network topological parameters in the human PPI network.  
273 Unlike the other two strains of viruses (PR8, Udorn), which are human-hosted, the highly  
274 pathogenic avian H5N1 influenza virus used in this paper is originally an avian influenza  
275 virus. This may explain the obvious differences in direct interactors and affected  
276 pathways. The H5N1 strain tends to have more interactions with human proteins and  
277 affect more cellular pathways than the other two strains. This implies that when avian  
278 influenza viruses managed to cross the host barriers infect human, the interactions  
279 between them are usually intense. However, for the viruses that have been circulating  
280 for a long time in human, like H1N1 and H3N2 influenza viruses, the interactions  
281 between the invader and the host become weaker.

282 The conservative patterns for all the three strains of influenza viruses at the N2  
283 protein level and the pathway level highlight that pathogens have some common  
284 attacking patterns to infect human. Some pathways that are related to all the three  
285 strains of viruses are selected. The viral proteins employed to target at these conserved  
286 pathways are different for different viruses, suggesting more subtype-specific pathogenic

287 mechanisms need more research work.

## 288 **Materials and Methods**

### 289 1. Antibodies and Reagents.

290 Antibodies for I $\kappa$ B $\alpha$ ,  $\alpha$ -Tubulin, Flag, HA, MyC, phospho-I $\kappa$ B $\alpha$  and phospho-IKK $\alpha$   
291 were purchased from Cell Signaling. Cell culture products were from Invitrogen and all  
292 other chemicals were Sigma-Aldrich products unless noted.

### 293 2. Cell Culture, Transfection, and Luciferase Reporter Assays.

294 293T (human embryonic kidney) cells were cultured in Dulbecco's modified Eagle's  
295 medium (DMEM, Gibco) supplemented with 10% heat-inactivated fetal bovine serum  
296 (FBS, Gibco), 2mM L-glutamine, 100U/mL penicillin, and 100mg/mL streptomycin.  
297 Transient transfections were performed with Lipofectamine 2000 (Invitrogen) according  
298 to the manufacturer's instructions.

299 Luciferase activity was determined by using the dual luciferase assay kit (Promega)  
300 according to the manufacturer's instructions.

### 301 3. Immunoprecipitation and Immunoblotting

302 Immunoprecipitation was performed using IP buffer (1% NP40, 50mM Tris-HCl [pH  
303 7.5], 150mM NaCl, and Complete<sup>TM</sup> protease inhibitor cocktail-EDTA (Roche)). Whole  
304 cell extracts were prepared after transfection and incubated with indicated antibodies  
305 together with Protein A/G beads (Roche) overnight. Beads were then washed 4 times

306 with IP buffer, and immunoprecipitates were eluted with SDS loading buffer (TransGen  
307 Biotech) and resolved in SDS-PAGE gels. The proteins were transferred to PVDF  
308 membrane (Bio-Rad) and further incubated with the indicated antibodies. The  
309 antigen-antibody complexes were visualized by the Immubilon™ chemiluminescent  
310 detection kit (Millipore).

#### 311 4. Statistical Analysis.

312 Analyses were done with the statistical software SAS/STAT. Data analysis over time  
313 was undertaken by repeated-measures analysis with SAS/STAT. Differences were  
314 considered statistically significant if the P value was <0.05.

#### 315 5. Human Protein-Protein Interaction Network

316 We use all the protein-protein interaction for homo sapiens in the BioGRID  
317 interaction database. The database version is 3.2.106. We choose all the physical  
318 interactions in the database, while the genetic interactions are excluded. In total, the PPI  
319 network contains 127950 interactions among 14924 human proteins.

#### 320 6. Protein Centrality Analyses

321 Based on the human PPI network constructed, we calculated the degree of each  
322 node in the network. And the NC centrality based on edge clustering coefficient are  
323 calculated by using the following equation:

$$324 \quad NC(v) = \sum_{u \in N_v} \frac{z_{v,u}}{\min(d_v - 1, d_u - 1)} \quad [40],$$

325 where  $z_{v,u}$  denotes the number of triangles that include the edge actually in the



326 network,  $d_u$  and  $d_v$  are degrees of node  $u$  and node  $v$ , and  $N_v$  denotes the set  
327 of all neighbors of node  $v$ .

## 328 7.KEGG Pathways

329 We download the KGML files at the KEGG pathway database for the pathways  
330 belongs to the following categories: immune system pathways, the cell growth and  
331 death pathways and the signal transduction pathways and pathways about inflammation.  
332 Then, we parse these KGML files by using python programs to obtain the genes that  
333 participated in each pathway.

## 334 **Acknowledgments**

335 This work was supported by the National Natural Science Foundation of China  
336 (31800136), Beijing Nova Program (Z171100001117120), Independent Research Project  
337 from State Key Laboratory of Pathogen and Biosecurity (SKLPBS1807) and Military  
338 Medical Science and Technology Youth Development Program (18QNP037).

## 339 **Author contributions**

340 Hongguang Ren, Long Liang and Junjie Yue conceived and supervised the study.  
341 Ting Song and Hongguang Ren designed the experiments. Yujie Wang, Ting Song and  
342 Kaiwu Li performed the experiments. Hongguang Ren and Yuan Jin analyzed the data.  
343 Hongguang Ren and Yujie Wang wrote the manuscript. Yujie Wang and Ting Song  
344 contributed equally to this work.

345 **Reference**

- 346 1. Nelson, M.I. and A.L. Vincent, *Reverse zoonosis of influenza to swine: new*  
347 *perspectives on the human-animal interface*. Trends in microbiology, 2015. **23**(3):  
348 p. 142-153.
- 349 2. Gerber, M., et al., *Selective packaging of the influenza A genome and*  
350 *consequences for genetic reassortment*. Trends Microbiol, 2014. **22**(8): p. 446-55.
- 351 3. Skehel, J.J. and A.J. Hay, *Influenza Virus Transcription*. Journal of General  
352 Virology, 1978. **39**(1): p. 1-8.
- 353 4. Lamb, R.A. and R.M. Krug, *In Fields Virology 4th edn*, ed. B.N. eds Fields, Knipe, D.  
354 M. & Howley, P. M. 2001: Lippincott-Raven, Philadelphia.
- 355 5. Tong, S., et al., *New World Bats Harbor Diverse Influenza A Viruses*. PLOS  
356 Pathogens, 2013. **9**(10): p. e1003657.
- 357 6. Webster, R.G., et al., *Evolution and ecology of influenza A viruses*. Microbiological  
358 reviews, 1992. **56**(1): p. 152-179.
- 359 7. Horimoto, T. and Y. Kawaoka, *Influenza: lessons from past pandemics, warnings*  
360 *from current incidents*. Nature Reviews Microbiology, 2005. **3**: p. 591.
- 361 8. Zhou, J., et al., *Characterization of the H5N1 highly pathogenic avian influenza*  
362 *virus derived from wild pikas in China*. J Virol, 2009. **83**(17): p. 8957-64.
- 363 9. Westgeest, K.B., et al., *Genomewide analysis of reassortment and evolution of*  
364 *human influenza A(H3N2) viruses circulating between 1968 and 2011*. J Virol,

- 365           2014. **88**(5): p. 2844-57.
- 366   10.   Petrova, V.N. and C.A. Russell, *The evolution of seasonal influenza viruses*. Nat  
367           Rev Microbiol, 2018. **16**(1): p. 47-60.
- 368   11.   Su, S., et al., *Epidemiology, Evolution, and Recent Outbreaks of Avian Influenza*  
369           *Virus in China*. Journal of Virology, 2015. **89**(17): p. 8671.
- 370   12.   Reid, A.H., et al., *Origin and evolution of the 1918 "Spanish" influenza virus*  
371           *hemagglutinin gene*. Proceedings of the National Academy of Sciences, 1999.  
372           **96**(4): p. 1651.
- 373   13.   Smith, G.J.D., et al., *Origins and evolutionary genomics of the 2009 swine-origin*  
374           *H1N1 influenza A epidemic*. Nature, 2009. **459**: p. 1122.
- 375   14.   Yuen, K.Y., et al., *Clinical features and rapid viral diagnosis of human disease*  
376           *associated with avian influenza A H5N1 virus*. Lancet, 1998. **351**(9101): p. 467-71.
- 377   15.   WHO, *Cumulative number of confirmed human cases for avian influenza A(H5N1)*  
378           *reported to WHO*. 2018. **1 November 2018**.
- 379   16.   Simon, P.F., et al., *Highly Pathogenic H5N1 and Novel H7N9 Influenza A Viruses*  
380           *Induce More Profound Proteomic Host Responses than Seasonal and Pandemic*  
381           *H1N1 Strains*. Journal of Proteome Research, 2015. **14**(11): p. 4511-4523.
- 382   17.   Hayden, M.S. and S. Ghosh, *Shared principles in NF-kappaB signaling*. Cell, 2008.  
383           **132**(3): p. 344-62.
- 384   18.   Kobayashi, T. and R. Kageyama, *Dynamic advances in NF-kappaB signaling*  
385           *analysis*. Sci Signal, 2009. **2**(81): p. pe47.

- 386 19. Shih, R.-H., C.-Y. Wang, and C.-M. Yang, *NF-kappaB Signaling Pathways in*  
387 *Neurological Inflammation: A Mini Review*. *Frontiers in Molecular Neuroscience*,  
388 2015. **8**: p. 77.
- 389 20. Hayden, M.S. and S. Ghosh, *Signaling to NF- $\kappa$ B*. *Genes & Development*, 2004.  
390 **18**(18): p. 2195-2224.
- 391 21. Zheng, J.W., et al., *NF-kappaB/P65 signaling pathway: a potential therapeutic*  
392 *target in postoperative cognitive dysfunction after sevoflurane anesthesia*. *Eur*  
393 *Rev Med Pharmacol Sci*, 2017. **21**(2): p. 394-407.
- 394 22. Sun, S.-C., *The non-canonical NF- $\kappa$ B pathway in immunity and inflammation*.  
395 *Nature Reviews Immunology*, 2017. **17**: p. 545.
- 396 23. Vallabhapurapu, S. and M. Karin, *Regulation and Function of NF- $\kappa$ B Transcription*  
397 *Factors in the Immune System*. *Annual Review of Immunology*, 2009. **27**(1): p.  
398 693-733.
- 399 24. Denk, A., et al., *Activation of NF- $\kappa$ B via the I $\kappa$ B Kinase Complex Is Both Essential*  
400 *and Sufficient for Proinflammatory Gene Expression in Primary Endothelial Cells*.  
401 *Journal of Biological Chemistry*, 2001. **276**(30): p. 28451-28458.
- 402 25. Durand, J.K. and A.S. Baldwin, *Chapter Three - Targeting IKK and NF- $\kappa$ B for*  
403 *Therapy*, in *Advances in Protein Chemistry and Structural Biology*, R. Donev,  
404 Editor. 2017, Academic Press. p. 77-115.
- 405 26. Kondylis, V., et al., *The interplay of IKK, NF-kappaB and RIPK1 signaling in the*  
406 *regulation of cell death, tissue homeostasis and inflammation*. *Immunol Rev*,

- 407 2017. **277**(1): p. 113-127.
- 408 27. Brightbill, H.D., et al., *Conditional Deletion of NF- $\kappa$ B-Inducing Kinase (NIK) in*  
409 *Adult Mice Disrupts Mature B Cell Survival and Activation*. The Journal of  
410 Immunology, 2015. **195**(3): p. 953.
- 411 28. Duncan, M.C., et al., *Bacterial internalization is required to trigger NIK-dependent*  
412 *NF- $\kappa$ B activation in response to the bacterial type three secretion system*. PLOS  
413 ONE, 2017. **12**(2): p. e0171406.
- 414 29. Cildir, G., K.C. Low, and V. Tergaonkar, *Noncanonical NF-kappaB Signaling in*  
415 *Health and Disease*. Trends Mol Med, 2016. **22**(5): p. 414-429.
- 416 30. Rahman, M.M. and G. McFadden, *Modulation of NF-kappaB signalling by*  
417 *microbial pathogens*. Nat Rev Microbiol, 2011. **9**(4): p. 291-306.
- 418 31. Liu, Q., et al., *Human Bocavirus NS1 and NS1-70 Proteins Inhibit*  
419 *TNF-alpha-Mediated Activation of NF-kappaB by targeting p65*. Sci Rep, 2016. **6**:  
420 p. 28481.
- 421 32. Franz, S., et al., *Mumps Virus SH Protein Inhibits NF-kappaB Activation by*  
422 *Interacting with Tumor Necrosis Factor Receptor 1, Interleukin-1 Receptor 1, and*  
423 *Toll-Like Receptor 3 Complexes*. J Virol, 2017. **91**(18).
- 424 33. Brady, G., et al., *Molluscum Contagiosum Virus Protein MC005 Inhibits*  
425 *NF-kappaB Activation by Targeting NEMO-Regulated I kappa B Kinase Activation*. J  
426 Virol, 2017. **91**(15).
- 427 34. Brinkmann, M.M., et al., *Modulation of host gene expression by the K15 protein*

- 428            *of Kaposi's sarcoma-associated herpesvirus*. J Virol, 2007. **81**(1): p. 42-58.
- 429    35.    Dufrasne, F.E., et al., *Modulation of the NF-kappaB signaling pathway by the*  
430            *HIV-2 envelope glycoprotein and its incomplete BST-2 antagonism*. Virology, 2018.  
431            **513**: p. 11-16.
- 432    36.    Gao, S., et al., *Influenza A virus-encoded NS1 virulence factor protein inhibits*  
433            *innate immune response by targeting IKK*. Cell Microbiol, 2012. **14**(12): p.  
434            1849-66.
- 435    37.    Shapira, S.D., et al., *A Physical and Regulatory Map of Host-Influenza Interactions*  
436            *Reveals Pathways in H1N1 Infection*. Cell, 2009. **139**(7): p. 1255-1267.
- 437    38.    Portela, A.n. and P. Digard, *The influenza virus nucleoprotein: a multifunctional*  
438            *RNA-binding protein pivotal to virus replication*. Journal of General Virology,  
439            2002. **83**(4): p. 723-734.
- 440    39.    Stark, C., et al., *BioGRID: a general repository for interaction datasets*. Nucleic  
441            Acids Res, 2006. **34**(Database issue): p. D535-9.
- 442    40.    Wang, J., et al., *Identification of essential proteins based on edge clustering*  
443            *coefficient*. IEEE/ACM Trans Comput Biol Bioinform, 2012. **9**(4): p. 1070-80.
- 444    41.    Dyer, M.D., T.M. Murali, and B.W. Sobral, *The landscape of human proteins*  
445            *interacting with viruses and other pathogens*. PLoS Pathog, 2008. **4**(2): p. e32.
- 446    42.    Yu, H., et al., *The importance of bottlenecks in protein networks: correlation with*  
447            *gene essentiality and expression dynamics*. PLoS Comput Biol, 2007. **3**(4): p. e59.
- 448    43.    Kanehisa, M. and S. Goto, *KEGG: kyoto encyclopedia of genes and genomes*.

449 Nucleic Acids Res, 2000. **28**(1): p. 27-30.

## 450 **Figure Legends**

451 **Figure. 1 H5N1 NP and H1N1 NP have different impacts on TNF- $\alpha$ -induced NF- $\kappa$ B**

452 **activation.** Fig. 1A and Fig. 1B 293T cells in 24-well plates were cotransfected with 125

453 ng pNF- $\kappa$  B-luc, 25 ng pRL-TK and indicated amount of H5N1 NP or H1N1 NP

454 expression plasmid, or empty vector for 24 h. Cells were then mock-treated or treated

455 with TNF- $\alpha$  (10 ng/ml) for 6 h. Reporter activity was determined by dual-luciferase

456 reporter assays. The resultant ratios were normalized to the fold-change value by that of

457 TNF- $\alpha$  -untreated cells cotransfected with empty vector, pNF- $\kappa$  B-luc and pRL-TK. Fig.

458 1C 293T cells were cotransfected with indicated amount of H5N1 NP and TAK1

459 expression plasmid, or empty vector for 24 h. Whole cell extracts were prepared by NP40

460 lysates and incubated with HA antibodies together with Protein A/G beads for 2 h. Beads

461 were then washed 4 times with IP buffer, and immunoprecipitates were eluted with SDS

462 loading buffer and resolved in SDS-PAGE gels. The proteins were transferred to PVDF

463 membrane and further incubated with the indicated antibodies. Fig. 1D 293T cells were

464 cotransfected with indicated amount of H5N1 NP and IKK $\alpha$  expression plasmid, or

465 empty vector for 24 h. Whole cell extracts were prepared by NP40 lysates and incubated

466 with MyC antibodies together with Protein A/G beads for 2 h. Beads were then washed 4

467 times with IP buffer, and immunoprecipitates were eluted with SDS loading buffer and

468 resolved in SDS-PAGE gels. The proteins were transferred to PVDF membrane and

469 further incubated with the indicated antibodies. Fig. 1E 293T cells were cotransfected  
470 with H5N1 NP or empty vector for 24 h. Cells were then mock-treated or treated with  
471 TNF- $\alpha$  (10 ng/ml) for 6 h. The cells were eluted with SDS loading buffer and resolved in  
472 SDS-PAGE gels. The proteins were transferred to PVDF membrane and further incubated  
473 with the IKK $\alpha$  phosphorylation antibodies.

474 **Figure. 2 H5N1 NA and H1N1 NA have different impacts on TNF- $\alpha$ -induced NF- $\kappa$ B**

475 **activation.** Fig. 2A and Fig. 2B 293T cells in 24-well plates were cotransfected with 125  
476 ng pNF- $\kappa$  B-luc, 25 ng pRL-TK and indicated amount of H5N1 NA or H1N1 NA  
477 expression plasmid, or empty vector for 24 h. Cells were then mock-treated or treated  
478 with IL-1 $\beta$  (10 ng/ml) for 6 h. Reporter activity was determined by dual-luciferase  
479 reporter assays. The resultant ratios were normalized to the fold-change value by that of  
480 IL-1 $\beta$  -untreated cells cotransfected with empty vector, pNF- $\kappa$  B-luc and pRL-TK. Fig.  
481 2C 293T cells were cotransfected with indicated amount of H5N1 NA and TAB2  
482 expression plasmid, or empty vector for 24 h. Whole cell extracts were prepared by NP40  
483 lysates and incubated with MyC antibodies together with Protein A/G beads for 2 h.  
484 Beads were then washed 4 times with IP buffer, and immunoprecipitates were eluted with  
485 SDS loading buffer and resolved in SDS-PAGE gels. The proteins were transferred to  
486 PVDF membrane and further incubated with the indicated antibodies. Fig. 2D 293T cells  
487 were cotransfected with indicated amount of H1N1 NA and IKK $\beta$  expression plasmid, or  
488 empty vector for 24 h. Whole cell extracts were prepared by NP40 lysates and incubated  
489 with MyC antibodies together with Protein A/G beads for 2 h. Beads were then washed 4



490 times with IP buffer, and immunoprecipitates were eluted with SDS loading buffer and  
491 resolved in SDS-PAGE gels. The proteins were transferred to PVDF membrane and  
492 further incubated with the indicated antibodies.

493 **Figure 3. Influenza-Human PPI interactions of an H5N1 virus.** Each circle represents  
494 a protein, green represents viral proteins and red represents host proteins. The interactions  
495 between influenza proteins and the human proteins are indicated by lines connecting the  
496 circles.

497 **Figure 4. Venn Graphs of (A) N1 proteins and (B) N2 proteins for the three strains**  
498 **of influenza viruses.**

499 **Figure 5. Viral proteins of the three strains of influenza viruses are shown with their**  
500 **direct interactors' membership in the selected 65 pathways.** Each shaded square in  
501 the figure represent the corresponding viral protein in the vertical direction interacts with  
502 some human proteins involved in the pathway in the horizontal direction.

503 **Figure. S1 The potential targets of H5N1 NP on the NF- $\kappa$ B signaling pathway are**  
504 **IKK $\alpha$  and the complex of TAK.** 293T cells in 24-well plates were cotransfected with  
505 125 ng pNF- $\kappa$  B-luc, 25 ng pRL-TK and indicated amount of H5N1 NP expression  
506 plasmid, or empty vector for 24 h. Cells were cotransfected with TRAF2, TAK1 and  
507 TAB1, TAB2, IKK $\alpha$ , IKK $\beta$ , respectively. Reporter activity was determined by  
508 dual-luciferase reporter assays. The resultant ratios were normalized to the fold-change  
509 value by that of TRAF2, TAK1 and TAB1, TAB2, IKK $\alpha$ , IKK $\beta$ -untreated cells  
510 cotransfected with empty vector, pNF- $\kappa$  B-luc and pRL-TK.

511 **Figure. S2 The potential target of H5N1 NA on the NF- $\kappa$ B signaling pathway is the**  
512 **complex of TAK.** 293T cells in 24-well plates were cotransfected with 125 ng pNF- $\kappa$   
513 B-luc, 25 ng pRL-TK and indicated amount of H5N1 NA expression plasmid, or empty  
514 vector for 24 h. Cells were cotransfected with TRAF6, TAK1 and TAB1, TAB2, IKK $\alpha$ ,  
515 IKK $\beta$ , respectively. Reporter activity was determined by dual-luciferase reporter assays.  
516 The resultant ratios were normalized to the fold-change value by that of TRAF6, TAK1  
517 and TAB1, TAB2, IKK $\alpha$ , IKK $\beta$ -untreated cells cotransfected with empty vector, pNF- $\kappa$   
518 B-luc and pRL-TK.

519 **Figure. S3 The potential targets of H1N1 NA on the NF- $\kappa$ B signaling pathway are**  
520 **TAB2 and IKK $\beta$ .** 293T cells in 24-well plates were cotransfected with 125 ng pNF- $\kappa$   
521 B-luc, 25 ng pRL-TK and indicated amount of H1N1 NA expression plasmid, or empty  
522 vector for 24 h. Cells were cotransfected with TRAF6, TAK1 and TAB1, TAB2, IKK $\alpha$ ,  
523 IKK $\beta$ , respectively. Reporter activity was determined by dual-luciferase reporter assays.  
524 The resultant ratios were normalized to the fold-change value by that of TRAF6, TAK1  
525 and TAB1, TAB2, IKK $\alpha$ , IKK $\beta$ -untreated cells cotransfected with empty vector, pNF- $\kappa$   
526 B-luc and pRL-TK.

527

528 Table S1. Viral-Host protein-protein interactions of the H5N1 virus

529

530 Table S2. Relations between the influenza A viruses and the selected pathways.

Figure 1






Figure 2


**A**



**B**



**C**



**D**








Figure 4



A



B

